Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016

WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza. Centers for Disease Control and Prevention. Atlanta, GA, USA.
World Health Organization, Global Influenza Programme. Geneva, Switzerland.
The Francis Crick Institute. Worldwide Influenza Centre., WHO Collaborating Centre for Reference and Research on Influenza. London., United Kingdom
WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza. Centers for Disease Control and Prevention. Atlanta, GA, USA.
The Francis Crick Institute. Worldwide Influenza Centre., WHO Collaborating Centre for Reference and Research on Influenza. London., United Kingdom
WHO Collaborating Centre for Reference and Research on Influenza. National Institute for Viral Disease Control and Prevention. Collaboration Innovation Centre for Diagnosis and Treatment of Infectious Diseases. China CDC, Beijing, China.
WHO Collaborating Centre for Reference and Research on Influenza. Peter Doherty Institute for Infection and Immunity. Melbourne, Victoria, Australia / University of Melbourne. Department of Microbiology and Immunology. Victoria, Australia.
WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza. Centers for Disease Control and Prevention. Atlanta, GA, USA.
National Infection Service. Public Health England. London, United Kingdom.
WHO Collaborating Centre for Reference and Research on Influenza. Peter Doherty Institute for Infection and Immunity. Melbourne, Victoria, Australia.
Public Health Laboratory Centre., 382 Nam Cheong Street. Hong Kong, China.
World Health Organization Regional Office for Europe. Division of Health Emergencies and Communicable Diseases. Copenhagen, Denmark.
National Institute of Health. Influenza Pathogenesis and Antiviral Resistance Laboratory. Lisboa, Portugal / Universidade de Lisboa. Faculdade de Farmácia. Lisboa, Portugal.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratórios.Rio de Janeiro, RJ. Brasil.
National Institute of Infectious Diseases. WHO Collaborating Centre for Reference and Research on Influenza. Tokyo, Japan.
National Institute of Infectious Diseases. WHO Collaborating Centre for Reference and Research on Influenza. Tokyo, Japan.
WHO Collaborating Centre for Reference and Research on Influenza. National Institute for Viral Disease Control and Prevention. Collaboration Innovation Centre for Diagnosis and Treatment of Infectious Diseases.China CDC, Beijing, China.
World Health Organization, Global Influenza Programme. Geneva, Switzerland.
National Institute for Public Health and the Environment. Bilthoven, The Netherlands.

Abstract

Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) assessed antiviral susceptibility of 14,330 influenza A and B viruses collected by WHO-recognized National Influenza Centres (NICs) between May 2015 and May 2016. Neuraminidase (NA) inhibition assay was used to determine 50% inhibitory concentration (IC50) data for NA inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. Furthermore, NA sequences from 13,484 influenza viruses were retrieved from public sequence databases and screened for amino acid substitutions (AAS) associated with reduced inhibition (RI) or highly reduced inhibition (HRI) by NAIs. Of the viruses tested by WHO CCs 93% were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 0.8% (n = 113) exhibited either RI or HRI by at least one of four NAIs. As in previous seasons, the most common NA AAS was H275Y in A(H1N1)pdm09 viruses, which confers HRI by oseltamivir and peramivir. Two A(H1N1)pdm09 viruses carried a rare NA AAS, S247R, shown in this study to confer RI/HRI by the four NAIs. The overall frequency of A(H1N1)pdm09 viruses containing NA AAS associated with RI/HRI was approximately 1.8% (125/6915), which is slightly higher than in the previous 2014-15 season (0.5%). Three B/Victoria-lineage viruses contained a new AAS, NA H134N, which conferred HRI by zanamivir and laninamivir, and borderline HRI by peramivir. A single B/Victoria-lineage virus harboured NA G104E, which was associated with HRI by all four NAIs. The overall frequency of RI/HRI phenotype among type B viruses was approximately 0.6% (43/7677), which is lower than that in the previous season. Overall, the vast majority (>99%) of the viruses tested by WHO CCs were susceptible to all four NAIs, showing normal inhibition (NI). Hence, NAIs remain the recommended antivirals for treatment of influenza virus infections. Nevertheless, our data indicate that it is prudent to continue drug susceptibility monitoring using both NAI assay and sequence analysis.

Keywords in Portuguese

Neuraminidase
Inibidor
Vigilância entomológica
Suscetibilidade
Resistência
Marcadores

Keywords

Neuraminidase
Inhibitor
Susceptibility
Surveillance
Resistance
Markers

Publisher

Elsevier Masson

Citation

GUBAREVA, Larisa V. et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016, Antiviral Research, v.146, p.12-20, Aug. 2017.

DOI

10.1016/j.antiviral.2017.08.004

ISSN

0166-3542

Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/24830

Type

Copyright

Restricted access

Embargo date

2030-01-01

Collections

Share

Statistics

Metadata

Author

Affilliation